Genzyme wraps up $345m acquisition of Bioenvision
607613
Genzyme Corp. said it completed its $345 million acquisition of Bioenvision Inc. despite complaints by some Bioenvision shareholders the price the Cambridge biotech offered was too low. Genzyme initially tried to take control of the New York biotech through a tender offer, but managed to acquire only 22 percent of shares that way. Bioenvision then tried to persuade a majority ...
301333
NEW YORK  - Genzyme Corp. announced  Wednesday that its drug Clolar has been approved by the U.S.  Food and Drug Administration (FDA) for the treatment of  children with difficult or relapsed acute lymphoblastic  leukemia (ALL).
246930
Biotechnology company Genzyme Corp  reported a fourth-quarter profit on Wednesday, reversing a year-earlier loss, as sales of its drugs for rare diseases increased.
618409
In a surprise attempt by a Cambridge biotechnology company to trump a takeover bid by one of its neighbors, Millennium Pharmaceuticals Inc. yesterday said it had reached a $515 million deal to buy a small Canadian drug firm that Genzyme Corp. has been trying to buy since late last month.
64992
Medarex Inc., a Princeton, NJ, biotechnology company, could receive up to $510 million under a global collaboration deal it signed with New York-based Pfizer Inc.
572919
Biotech titan Genzyme (Nasdaq: GENZ) has its roots in the treatment of rare genetic diseases and also has a significant presence in the treatment of renal diseases and providing diagnostic testing services.
620527
Dutch-Swedish pharmaceutical group Akzo Nobel said on Monday that it had agreed to sell its Organon BioSciences drugs unit to US rival Schering-Plough for 11 billion euros (14.4 billion dollars).
729447
U.S. antitrust authorities on Wednesday approved AstraZeneca Plc's  plan to buy biotechnology company MedImmune Inc.  for more than $15 billion.
401679
Genzyme Corp. suffered an unaccustomed defeat yesterday when shareholders in Bioenvision Inc. , a small New York cancer-drug developer, blocked a $350 million takeover bid by refusing to sell their stock to the Cambridge biotechnology giant.
234249
Moving to strengthen its offerings to treat cancer, Biogen Idec Inc. of Cambridge yesterday signed a deal to license tumor-killing technology from ImmunoGen Inc.
421111
Genzyme Corp.  said on Friday its osteoarthritis pain treatment Synvisc will retain a separate, higher reimbursement rate, after the U.S. government reversed its earlier decision to cut the rate, sending Genzyme shares higher.
287707
Serono SA , one of the world's largest biotechnology companies, was bought yesterday by German chemical giant Merck KGaA in a deal worth more than $13 billion.
356950
Consolidation in Europe's drugs   sector gathered steam on Thursday as Germany's Merck unveiled a   $13.3-billion deal to buy Europe's top biotech firm Serono, and   Denmark's Nycomed won the drugs unit of Altana.
494130
Genzyme Corp. announced Wednesday that its drug Clolar has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of children with difficult or relapsed acute lymphoblastic leukemia (ALL).
260459
Diversified manufacturer 3M Co.  on Wednesday said it has agreed to buy for Biotrace International PLC , a U.K.-based maker of industrial microbiology products, for about $98 million.
423442
Gilead Sciences Inc. , the world's third-biggest biotechnology company, said on Monday it has agreed to acquire Myogen Inc.  for $2.5 billion in a surprise transaction that gives Gilead access to Myogen's experimental hypertension drugs.
20790
In a rare hostile bid, Genzyme said it would make an offer for AnorMed, a Canadian company that had spurned previous acquisition approaches.